YJA 203798
Alternative Names: YJA-20379-8Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Yung-Jin Pharmaceutical
- Class Antiulcers; Naphthyridines
- Mechanism of Action Proton pump inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Peptic ulcer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Peptic-ulcer in South Korea (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Peptic-ulcer in South Korea (PO)
- 11 Oct 2002 This compound is still in active development